awmsg logo



sodium valproate (Episenta®)


Reference No. 1178

Publication date:
12/01/2012


Appraisal information

sodium valproate (Episenta®) 150 mg prolonged-release capsule
sodium valproate (Episenta®) 300 mg prolonged-release capsule
sodium valproate (Episenta®) 500 mg prolonged-release granules
sodium valproate (Episenta®) 1000 mg prolonged-release granules


Company: Beacon Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 03/11/2011
AWMSG meeting date: 07/12/2011
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2111
Ministerial ratification: 09/01/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sodium valproate (Episenta®) is recommended as an option for use within NHS Wales for the treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate (Episenta®) for acute mania. AWMSG is of the opinion that sodium valproate (Episenta®) may be suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download